Knockout of LINC01134 as a potential treatment for Liver Cancer in HepG2 cells
DOI:
https://doi.org/10.61173/btwtm605Keywords:
HCC, LncRNA, TLNC1, HepG2, p53, KnockoutAbstract
Liver cancer, a major global health issue, continues to contribute significantly to global deaths. Hepatocellular carcinoma (HCC), the most prevalent primary liver cancer, remains a leading cause of cancer-related fatalities. This study explores the potential treatment for HCC by investigating the role of LINC01134, an encoding gene for the LncRNA TLNC1, in mediating the nuclear export of p53. The hypothesis suggests that knocking out the LINC01134 gene in HepG2 cells will decrease p53 nuclear export, leading to increased p53 levels and enhanced cellular responses to DNA damage. The methods include CRISPR CAS-9 for gene knockout, RT-PCR for TLNC1 expression, Immunofluorescence for p53 within the nucleus, and xenograft mouse model for in vivo tumor size reduction. Statistical analysis will be performed using a one-sample T-test. This strategy might effectively improve the cell’s reaction to DNA damage, which could halt or slow the growth of HCC.
References
[1] Cancer. (n.d.). Retrieved December 28, 2023, from https:// www.who.int/health-topics/cancer
[2] Cancer. (n.d.). Retrieved December 28, 2023, from https:// www.who.int/news-room/fact-sheets/detail/cancer
[3] Balogh, J., Victor, D., Asham, E. H., Burroughs, S. G., Boktour, M., Saharia, A., Li, X., Ghobrial, R. M., & Monsour, H. P. (2016). Hepatocellular carcinoma: A review. Journal of Hepatocellular Carcinoma, 3, 41–53. https://doi.org/10.2147/ JHC.S61146
[4] Yuan, K., Lan, J., Xu, L., Feng, X., Liao, H., & Xie, K. (2022). Long noncoding RNA TLNC1 promotes the growth and metastasis of liver cancer via inhibition of p53 signaling. Molecular Cancer, 21. https://doi.org/10.1186/s12943-022- 01578-w
[5] F. Negri and C. Porta. “Donafenib in Chinese patients with advanced hepatocellular carcinoma (HCC): Really a new standard of care, or should we change paradigm for drug development in HCC?”. Oncology Reviews. vol. 15. no. 2. Sep. 2021. 10.4081/oncol.2021.564.
[6] A. P. Venook, C. N. Papandreou, J. Furuse and L. L. D. Guevara. “The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective .”Oncologist. vol. 15. no. S4. pp. 5-13. Nov. 2010. 10.1634/ theoncologist.2010-s4-05.
[7] Chen, J. (2016). The Cell-Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression. Cold Spring Harbor Perspectives in Medicine, 6(3), a026104. https:// doi.org/10.1101/cshperspect.a026104
[8] J. D. Yang and J. K. Heimbach, “New advances in the diagnosis and management of hepatocellular carcinoma,” BMJ, vol. 371, p. m3544, Oct. 2020, doi: 10.1136/bmj.m3544.
[9] Foroutan B. A Narrative Review of the TP53 and Its Product the p53 Protein. OBM Genetics 2023; 7(3): 185; doi:10.21926/ obm.genet.2303185. https://www.lidsen.com/journals/genetics/ genetics-07-03-185
[10] Liang, S. (2018). Towards transcriptome-wide studies of mRNA translation in tissues from cancer patients https:// openarchive.ki.se/xmlui/handle/10616/46427
[11] Surget, S., Khoury, M. P., & Bourdon, J.-C. (2013). Uncovering the role of p53 splice variants in human malignancy: A clinical perspective. OncoTargets and Therapy, 7, 57–68. https://doi.org/10.2147/OTT.S53876
[12] Sormunen, R., Eskelinen, S., & Lehto, V. P. (1993). Bile canaliculus formation in cultured HEPG2 cells. Laboratory investigation; a journal of technical methods and pathology, 68(6), 652–662.
[13] Shi, D., & Gu, W. (2012). Dual Roles of MDM2 in the Regulation of p53: Ubiquitination Dependent and Ubiquitination Independent Mechanisms of MDM2 Repression of p53 Activity. Genes & cancer, 3(3-4), 240–248. https://doi. Dean&Francis org/10.1177/1947601912455199
[14] Van Bergen, N. J., Bell, K. M., Carey, K., Gear, R., Massey, S., Murrell, E. K., Gallacher, L., Pope, K., Lockhart, P. J., Kornberg, A., Pais, L., Walkiewicz, M., Simons, C., Wickramasinghe, V. O., White, S. M., & Christodoulou, J. (2021). Pathogenic variants in nucleoporin TPR (translocated promoter region, nuclear basket protein) cause severe intellectual disability in humans. Human Molecular Genetics, 31(3), 362–375. https:// doi.org/10.1093/hmg/ddab248
[15] Beck, M., & Hurt, E. (2017). The nuclear pore complex: understanding its function through structural insight. Nature reviews Molecular cell biology, 18(2), 73-89.
[16] Statello, L., Guo, C.-J., Chen, L.-L., & Huarte, M. (2021). Gene regulation by long noncoding RNAs and its biological functions. Nature Reviews. Molecular Cell Biology, 22(2), 96–118. https://doi.org/10.1038/s41580-020-00315-9
[17] Begolli, R., Sideris, N., & Giakountis, A. (2019). LncRNAs as chromatin regulators in cancer: from molecular function to clinical potential. Cancers, 11(10), 1524.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
